Glaukos Co. (NYSE:GKOS) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. reduced its stake in Glaukos Co. (NYSE:GKOS) by 30.9% during the 4th quarter, Holdings Channel reports. The fund owned 38,855 shares of the medical instruments supplier’s stock after selling 17,340 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Glaukos were worth $5,826,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. IFP Advisors Inc purchased a new position in shares of Glaukos in the 4th quarter valued at about $43,000. Asset Planning Inc acquired a new position in Glaukos during the 4th quarter worth approximately $90,000. Picton Mahoney Asset Management purchased a new stake in shares of Glaukos in the 4th quarter valued at approximately $125,000. SBI Securities Co. Ltd. acquired a new stake in shares of Glaukos in the 4th quarter valued at $153,000. Finally, Smartleaf Asset Management LLC lifted its position in shares of Glaukos by 275.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock worth $164,000 after purchasing an additional 807 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Glaukos

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Alex R. Thurman sold 1,520 shares of the firm’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at $5,708,568.04. This represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 6.40% of the company’s stock.

Glaukos Stock Performance

Shares of GKOS stock opened at $88.17 on Tuesday. Glaukos Co. has a 52-week low of $77.91 and a 52-week high of $163.71. The stock’s 50-day moving average price is $106.99 and its 200 day moving average price is $131.11. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $4.99 billion, a PE ratio of -30.72 and a beta of 0.88.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The company had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. As a group, equities research analysts forecast that Glaukos Co. will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on GKOS. Mizuho decreased their price target on Glaukos from $200.00 to $175.00 and set an “outperform” rating for the company in a report on Wednesday, April 16th. Piper Sandler dropped their price target on shares of Glaukos from $180.00 to $165.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 15th. Truist Financial reduced their price objective on shares of Glaukos from $185.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, April 11th. Wells Fargo & Company increased their target price on shares of Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Finally, Needham & Company LLC boosted their price target on shares of Glaukos from $149.00 to $176.00 and gave the company a “buy” rating in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $156.17.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.